

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Clinical Nutrition ESPEN 48 (2022) 202-209

ELSEVIER

Contents lists available at ScienceDirect

Clinical Nutrition ESPEN

journal homepage: http://www.clinicalnutritionespen.com

Original article

The modified NUTRIC score (mNUTRIC) is associated with increased 28-day mortality in critically ill COVID-19 patients: Internal validation of a prediction model



CLINICAL NUTRITION ESPEN

Matteo Luigi Giuseppe Leoni ^{a, b, *}, Elisa Moschini ^a, Maurizio Beretta ^c, Marco Zanello ^d, Massimo Nolli ^a

^a Department of Anesthesia and Intensive Care Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy

^b Unit of Interventional Pain Management, Guglielmo da Saliceto Hospital, Piacenza, Italy

^c Department of Medicine and Surgery, University of Parma, School of Nursing, Piacenza, Italy

^d University Alma Mater Studiorum, Department of Biomedical and Neuromotor Sciences (DIBINEM), Bologna, Italy

A R T I C L E I N F O

Article history: Received 8 February 2022 Accepted 14 February 2022

Keywords: Coronavirus disease 2019 (COVID-19) Modified NUTRIC score (mNUTRIC) Nutritional risk assessment Intensive care unit Mortality

SUMMARY

Background: High prevalence of malnutrition was found in critically ill COVID-19 patients. The modified Nutrition Risk in the Critically ill (mNUTRIC) score is frequently used for nutritional risk assessment in intensive care unit (ICU) COVID-19 patients. The aim of this study was to investigate the role of mNUTRIC score to predict 28-day mortality in critically ill COVID-19 patients admitted to ICU.

Methods: A cohort of consecutive COVID-19 critically ill patients admitted to ICU was retrospectively evaluated and the nutritional risk was assessed with the use of mNUTRIC score. A multivariable Cox regression model to predict 28-day mortality was therefore developed including the mNUTRIC as a covariate. Internal validation was performed using the bootstrap resampling technique to reduce possible bias in the estimated risks. The performance of the prediction model was assessed via calibration and discrimination.

Results: A total of 98 critically ill COVID-19 patients with a median age of 66 years (56–73 IQR), 81 (82.7%) males were included in this study. A high nutritional risk (mNUTRIC \geq 5 points) was observed in 41.8% of our critically ill COVID-19 patients while a low nutritional risk (mNUTRIC <5 points) was observed in 58.2%. Forty-five patients (45.9%) died within 28 days after ICU admission. In multivariable model after internal validation, mNUTRIC \geq 5 (optimism adjusted HR 2.38, 95% CI 1.08–5.25, p = 0.02) and high-sensitivity C-reactive protein values (CRP) (optimism adjusted HR 1.02, 95% CI 1.01–1.07, p = 0.005) were independent predictors of 28-day mortality.

Conclusions: A high prevalence of malnutrition as revealed by mNUTRIC was found in our critically ill COVID-19 patients once admitted in ICU. After adjustment for covariables, mNUTRIC \geq 5 and CRP levels were independently associated with 28-day mortality in critically ill COVID-19 patients. The final model revealed good discrimination and calibration. Nutritional risk assessment is essential for the management of critically ill COVID-19 patients as well as for outcome prediction.

© 2022 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.

1. Introduction

Since the first diagnosis of the Coronavirus Disease 2019 (COVID-19) in China (Wuhan), in December 2019, a pandemic has

* Corresponding author. Department of Anesthesia and Intensive Care Unit, Unit of Interventional Pain Management, Guglielmo da Saliceto Hospital, via Taverna 49, 29121, Piacenza, Italy.

E-mail address: matteolg.leoni@gmail.com (M.L.G. Leoni).

spread rapidly across the globe. This outbreak has severely affected many countries and their healthcare systems [1]. Several risk factors have been identified to increase the mortality of critically ill COVID-19 patients. Hypertension, diabetes, cardiovascular disease, obesity, older age, higher SOFA score, lymphopenia and high levels of D-dimer, procalcitonin and LDH are associated with a severe form of the disease [2]. Malnutrition represents another independent risk factor for mortality in intensive care unit (ICU) patients [3] while the same findings were also found for COVID-19 critically ill

https://doi.org/10.1016/j.clnesp.2022.02.014

2405-4577/© 2022 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.

patients [4]. As recently underlined by the ESPEN (European Society of Parenteral and Enteral Nutrition) expert statement, the diagnosis and the treatment of malnutrition is one of the principal aims in the management of COVID-19 patients [5]. Moreover, the actual ESPEN guidelines suggest that early nutritional support should be considered in every patient with ICU stay longer than 2 days since a high risk of malnutrition can occur [6].

The Nutrition Risk in the Critically ill (NUTRIC) score, is a suggested screening tool for nutritional assessment of ICU patients [7] and the variable interleukin-6 (IL-6) was excluded in the modified NUTRIC (mNUTRIC) score [8]. Recently, the mNUTRIC score appeared as a promising tool to evaluate the outcome of ICU patients [9] and critically ill COVID-19 patients [10].

The aim of this study was to investigate the role of mNUTRIC score to predict 28-day mortality in critically ill COVID-19 patients admitted to ICU. Moreover, we evaluated the performance of APACHE II, SOFA, and mNUTRIC scoring systems and we verified the optimal mNUTRIC cut-off for outcome prediction.

2. Methods

2.1. Population

This study was approved by the Local Ethics Committee and was conducted at Guglielmo da Saliceto Hospital of Piacenza. We retrospectively analysed a cohort of consecutive critically ill patients admitted to our ICU from March 1, 2020 to May 31, 2020. Critically ill patients were defined as those admitted to ICU who required mechanical ventilation or needed a fraction of inspired oxygen (FiO₂) of at least 60% or more [11]. During the study period, our hospital was quickly changed into a "COVID-19 hospital" to manage a sudden increase in COVID-19 patients requiring hospital admission. Consequently, all the patients admitted to our ICU were COVID-19 patients. COVID-19 infection was diagnosed by a positive result of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs. Pregnant women, children and patients with negative RT-PCR assay were not included in the study.

2.2. Data collection

Electronic medical records were reviewed to collect demographic, clinical and laboratory data. Patients' clinical history including demographic data, medical comorbidities, COVID-19 symptoms duration before hospitalization were also collected. Complete blood cells count, C-reactive protein (CRP), creatinine, glucose, total bilirubin and procalcitonin were considered as laboratory data.

The mNUTRIC score was calculated for each patients within 24 h of ICU admission. This score (0–9 points) was calculated based on five variables: age, acute physiology and chronic health assessment II score (APACHE II), Sequential Organ Failure Assessment (SOFA) score, number of comorbidities and pre-ICU hospital length of stay [10]. The patients were divided in two group based on the mNU-TRIC score [10]: high nutritional risk (\geq 5 points) and low nutritional risk (<5 points).

During the ICU length of stay, every patient received a total energy intake of about 15-20 kcal/kg of actual body weight and the protein intake was 1.2-2 g/kg of actual body weight [12].

2.3. Sample-size calculation

Sample size was calculated based on a previously reported 28day mortality in critically ill Covid-19 patients equal to 87% and 49% in high and low nutritional risk group respectively [13]. The α (type I error) was set to 0.05 and power = 0.8. The ratio of cases between the low and high nutrition risk groups was set to 1:1. Consequently, a minimum number of 28 patients in the low and 28 patients in the high nutritional risk group were required.

2.4. Statistical analysis

Continuous variables are reported as median and interquartile range while categorical data as relative number and percentage. Mann–Whitney U test, χ^2 test, or Fisher's exact test were used to compare differences between survivors and non-survivors. Risk factors associated with 28 day-mortality were evaluated with a univariable and multivariable Cox proportional hazards regression.

The proportional hazard assumptions were tested and a forward regression analysis was used to select variables accepted in the multivariable model. The Akaike information criterion was used to compare different possible models and determine which one is the best fit for the data.

The internal validation of the model was assessed with nonparametric bootstrap (1000 replications) to obtain random bootstrap samples with replacement from the original database. The prediction model was therefore fitted on each of bootstrap samples. To adjust for optimism, the shrinkage factor (the average calibration slope from each of the bootstrap samples) was applied to the β coefficients of the multivariable model to obtain optimism adjusted hazard ratios for each variable [14].

Model performance was assessed via discrimination and calibration measures. A calibration curve was implemented by plotting predicted against observed probability using adaptive linear spline hazard regression [15].

The TRIPOD (transparent reporting of a multivariable model for individual prognosis or diagnosis) guidance was used to conduct this study and to report the results of the prediction model [16]. Results are expressed as hazard ratio with 95% confidence intervals (95%CI) and p values.

A logistic regression analysis and the area under the receiving operating characteristic (AUC) curve were used to assess the prognostic performance of mNUTRIC, SOFA score and APACHE II.

The Youden index method was used to define the optimal cutoff point of mNUTRIC that maximize the difference between true positive rate and false positive rate for all possible cut-off values [17].

Statistical significance was set at a two tailed P value < 0.05. STATA MP, version 16.0 (STATA Corp., Texas, USA) and R v4.0.3 (R Foundation for Statistical Computing, Vienna, Austria, www.rproject.org) were used for the analyses.

3. Results

98 patients with a confirmed SARS-CoV-2 infection and severe clinical disease expression requiring high-level intensive care treatment were admitted to our ICU during the study period. The median age of the patients was 66 years (56-73 IQR) and 81 patient (82.7%) were male. Almost one comorbidity was present in nearly 61% of patients of which hypertension was the most common (50%), followed by diabetes (19.4%) and heart disease (angina, myocardial infarction or heart failure), 17.3% (Table 1). The most common disease presentation were respiratory symptoms and fever (98% and 91% respectively), followed by gastrointestinal manifestations (vomiting and diarrhea), 16.3%. The median time from respiratory symptoms onset to hospital admission was not different in low nutritional risk group compared to high nutritional risk group (7 days, 6-10 IQR in low mNUTRIC group vs 7 days, IQR 7-10 days in high mNUTRIC group, p = 0.67). The same findings were observed for the length of hospital stay prior to ICU admission (5 days, 1–6

Table 1

Characteristics of the studied population.

Variable	Overall population
	(n = 98) n. (%)
Age, median (IQR), years	66 (56-73)
Gender	
Male	81 (82.7%)
Female	17 (17.3%)
Comorbidities	
Hypertension	48 (50%)
Diabetes	19 (19.4%)
Cardiovascular disease	17 (17.3%)
Chronic obstructive pulmonary disease	12 (12.2%)
Obesity (BMI \geq 30 kg/m2)	9 (9.2%)
Malignancy or history of cancer disease	8 (8.2%)
Chronic kidney disease	4 (4.1%)
Initial symptoms	
Respiratory symptoms	96 (98%)
Fever	89 (91%)
Gastrointestinal symptoms	16 (16.3%)
Cardiovascular symptoms	7 (7.1%)
Time from disease onset to ICU	12 (9–16)
admission, median (IQR), days	
SOFA score, median (IQR)	4 (3-5)
APACHE II score, median (IQR)	24 (15-26)
Duration of mechanical ventilation, days	9 (5-14)
Treatments in ICU	
CRRT	2 (2%)
Vasopressors	55 (56.1%)
Non-invasive ventilation (C-PAP, bi-level)	3 (3%)
Invasive mechanical ventilation	95 (97%)
Prone positioning	44 (45%)
28-day mortality	45 (46%)

IQR in low mNUTRIC group vs 6 days, 2-9 IQR in high mNUTRIC group, p = 0.28).

A total of 3% of patients received non-invasive ventilation at ICU admission while almost all the patients required invasive mechanical ventilation during the ICU length of stay. A high proportion of patients (56.1%) required vasopressors.

Forty-five patients (45.9%) died in hospital within 28 days after ICU admission and the median time from ICU admission to death was 18 days (IQR 8–43). The characteristics of the studied population is detailed in Table 1.

A high nutritional risk (mNUTRIC \geq 5 points) was found in 41.8% of the studied population while a low nutritional risk (mNUTRIC <5 points) was observed in 58.2%. The 28-day mortality was significantly higher in the in the high nutritional risk group than in the low nutritional risk group (80.5% vs 21.1%, p < 0.001) (Fig. 1). Differences between high nutritional risk group and low nutritional risk group are reported in Table 2.

Most of the patients (80%) received enteral nutrition (EN) while 5% received total parenteral nutrition (TPN) and 15% EN + parenteral nutrition (PN). Nasogastric tube was the principal feeding route since only one patient (1.02%) was fed via a nasal jejunal tube. Vomiting and gastric retention occurred in 45% of the patients, while 15% showed diarrhea and 70% hyperglycemia. No differences were found in terms of nutritional support (p = 0.78) and EN intolerance (p = 0.82) in low and high mNUTRIC groups.

Check of the proportionality assumption before regression revealed no violation (p = 0.30). At univariable analysis age (HR 1.03, 95% CI 1.00–1.06, p = 0.03), BMI \geq 30 (HR 2.08, 95% CI 1.06–4.10, p = 0.03), white blood cell count (HR 1.08, 95% CI 1.03–1.13, p = 0.002), neutrophils count (HR 1.08, 95% CI 1.03–1.14, p = 0.002), platelets count (HR 0.99, 95% CI 0.99–1.00, p = 0.05), high-sensitivity C-reactive protein value (HR 1.06, 95% CI 1.03–1.09, p < 0.001) and mNUTRIC \geq 5 (HR 6.48, 95% CI 3.31–12.69, p < 0.001) were significantly associated with 28-day mortality (Supplementary Table 1).

Based on the multivariable Cox proportional hazards regression analysis, two independent predictors were identified. mNUTRIC \geq 5 (HR 2.64, 95% CI 1.20–5.83, p = 0.02) and high-sensitivity C-reactive protein value (HR 1.13, 95% CI 1.12–1.19, p = 0.005) were significantly associated with 28-day mortality (Table 3). In the final internal validated multivariable Cox proportional hazards regression model, mNUTRIC \geq 5 (optimism adjusted HR 2.38, 95% CI 1.08–5.25, p = 0.02) and high-sensitivity C-reactive protein value (optimism adjusted HR 1.02, 95% CI 1.01–1.07, p = 0.005) were significantly associated with 28-day mortality (Table 3).

The C-statistic corrected for optimism/overfitting for the prediction of 28-day mortality showed a good discriminatory capacity (C-statistic = 0.72, 95% Cl 0.67-0.79). The calibration plot revealed a good calibration of the final model (slope = 0.80, intercept = 0.05) (Fig. 2).

When we compared the performance of different prediction scores for mortality prediction, APACHE-II had a lowest sensitivity of 74% and specificity of 38% (AUC = 0.62, 95%CI: 0.48–0.76), SOFA had 69% and 85% (AUC = 0.80, 95%CI: 0.71–0.84) respectively, whereas mNUTRIC score had the highest sensitivity of 75% and specificity of 89% (AUC = 0.90, 95%CI: 0.84–0.95), Supplementary Fig. 1. The optimal mNUTRIC cut-off associated with the highest Youden index was confirmed as 5 points score.

4. Discussion

The nutritional assessment in critically ill COVID-19 patients is an important element for outcome prediction. In this study patients with high nutritional risk (mNUTRIC \geq 5 points) at ICU admission showed an increased probability of 28-day mortality than those with low nutritional risk (mNUTRIC<5 points). Moreover, the mNUTRIC score had the highest sensitivity and specificity for outcome prediction compared to SOFA and APACHEII.

A high prevalence of malnutrition (37.5%) was recently reported in a general cohort of COVID-19 inpatients and 26% of them showed severe malnutrition [18]. The same findings were observed in elderly patients with COVID-19 in a cross sectional study in Wuhan, China [4]. Many possible features can lead to malnutrition in COVID-19 patients. The presence of dyspnea, dysgueusia, anosmia, anorexia, dysphagia, nausea, vomiting and diarrhea can decrease food intake. Simultaneously, caloric and protein intake may be inadequate during the pre-intubation period [5]. Moreover, our patients were kept at home for almost one week before being admitted in the emergency department and this could have influenced the nutritional status.

A state of hyper-metabolism and increased energy expenditure measured by indirect calorimetry were recently observed in a small cohort of critically ill COVID-19 patients [19]. Therefore, acute underfeeding is a possible consequence and it can lead to immuno-suppression and to inflammatory response impairment [20]. In fact, almost all our patients showed lymphopenia and even if this finding is common in critically ill COVID-19 patients [21], malnutrition can itself increase lymphopenia and the risk of infectious complications [22].

In ICU the prevalence of malnutrition in COVID-19 patients is even higher (66.7%) [23] and the hypermetabolic phase is prolonged up to 21 days since intubation [24].

The high prevalence of malnutrition in COVID-19 patients and the potential role of individualised nutritional support to improve clinical outcomes and survivals [25] suggest the need to screen the inpatients nutritional risk and to implement individualised nutritional support in patients at risk [26].

The NUTRIC score was developed as a scoring method for quantifying nutrition risk in ICU patients [27] and the American Society for Parenteral and Enteral Nutrition (ASPEN) recommended



Fig. 1. Survival probability in critically ill COVID-19 patients with high and low nutritional risk. Patients with high nutritional risk (mNUTRIC score \geq 5 points) showed a higher 28-day mortality than those with low nutritional risk (mNUTRIC score <5 points), log-rank p < 0.0001.

this score together with the Nutrition Risk Screening 2002 (NRS 2002) for nutritional risk screening in critically ill patients [7]. Conversely, the European Society for Parenteral and Enteral Nutrition (ESPEN) no longer recommended the use of NUTRIC score since is does not include nutritional parameters and it is heavily influenced by APACHE II and SOFA [6]. However, no standardized method currently exists to assess the patient nutritional risk in ICU. The mNUTRIC was the evolution of NUTRIC since IL-6 value was removed from the score because the contribution of this variable was not statistically and clinically useful [27]. Moreover, as it was recently noted, the mNUTRIC and NRS-2002 scores have similar performance in predicting hospital mortality but the mNUTRIC has a better discriminatory ability for mortality prediction in critically ill patients [28]. In our study a high nutritional risk (mNUTRIC \geq 5 points) was found in 41.8% of the cohort and the probability for 28day mortality had more than doubled compared to low nutritional risk (mNUTRIC <5 points) patients. As is was recently reported by Zhang et al., a mNUTRIC score >5 was observed in 61% of critically ill COVID-19 patients and the mortality of this group (87%) was significantly higher than in the low nutritional risk group (49%) [13].

Our results are in line with this cited paper and the optimal mNUTRIC cut-off was confirmed as 5 points score for high nutritional risk assessment. On the contrary, almost all our patients required mechanical ventilation and the principal reason for ICU admission was related to the severity of respiratory failure. Since the median time from respiratory symptoms onset to ICU admission was 12 days (9–16 IQR), it is possible to argue that the increased catabolism and the poor nutritional intake worsened the respiratory failure. A global mortality of 46% was found in our critically ill COVID-19 patients and this data is in line with previous findings in our country [29].

Along with the nutritional risk assessment, a recently published meta-analysis showed that higher levels of inflammatory markers such as C-reactive protein (CRP) have been associated with COVID-19 severity and could be considered as prognostic factor [30]. Our predictive model showed that CRP plasmatic levels were independently associated with increased risk of 28-day mortality. In particular, for every increase in one point in CRP levels, the 28-day mortality hazard increased by 2%. It is noteworthy that our results are in keeping with previous studies reporting the role of increased CRP levels in predicting disease severity [31] and the need of mechanical ventilation [32] in COVID-19 patients. Moreover, a positive correlation between CRP concentrations and the extension of lung lesions was also found in COVID-19 patients [33].

Obesity is a frequently reported risk factor for ICU admission and the need of invasive mechanical ventilation [34]. On the contrary, in our multivariable analysis obesity was not a risk factor for mortality in ICU patients. It is important to note that only 9 patients in our cohort showed a BMI > 30 kg/m² in the high and in the low nutritional risk group. Consequently, this variable could have been underpowered. On the other hand, the mortality risk associated with the underweight is frequently reported with an excessively wide confidence interval [35]. However, as we previously found in a large cohort of critically ill COVID-19 patients, only morbid obesity $(BMI> 40 \text{ kg/m}^2)$ was a risk factors for death [36]. Probably, due to the inability of BMI to differentiate between fat and lean body mass and to account for edema and sodium retention, this variable is less useful for outcome prediction. Moreover, no significant associations was found between body composition and disease severity after bioelectric impedance measurements [37].

The validation of a prognostic model is a fundamental step to implement its use in clinical practice. As it was recently outlined, a possible risk of bias can occur in many prognostication model for patients with COVID-19 due to a lack of validation [38]. Therefore, we decided to use a bootstrap resampling technique for internal validation of our model. The bootstrap resampling draws random samples with replacement from the derivation cohort. Consequently, the prognostic model is evaluated both in the derivation cohort and in the bootstrap sample in order to assess its performance such as discrimination and calibration and to reduce the risk of potential false positive prediction estimates. The mNUTRIC score

M.L.G. Leoni, E. Moschini, M. Beretta et al.

Table 2

Differences in clinical characteristics and initial laboratory findings between high and low nutritional risk patients.

Age, modian (10,R), years Gender60:30-69)70 (64-73)0.001Male Female44 (833)47 (82.35)0.95Pemale71 (73)10 (17.53)Comorbidities71 (55.98)10 (17.53)Hypertension73 (55.98)61 (05.93)0.002Dabetes13 (31.73)61 (05.93)0.023Obesity (RM ≥30 kg/m²)13 (31.73)61 (05.93)0.023Comora obtractive pulmonary disease92 (23.13)84.8830.33Chronic obtractive pulmonary disease24.93321.3530.07Malignancy or history of cancer disease44.03358.8530.09Respiratory symptoms41.003358.8530.09Cardiovascular symptoms41.003358.8530.09Cardiovascular symptoms71.739.15.830.09Cardiovascular symptoms71.739.15.830.09Cardiovascular symptoms88.02-07)81.02-050.33Gastraintestinal symptoms88.03-37.20.31Respiratory rate, born88.03-37.20.390.33Temperature, "C88.03-37.20.090.33Temperature, "C88.03-63.720.010.01Vital parameters at LCU admission, median (10,8)12.5 (22-31.81)10.1 (65-13.4)0.01Vital parameters at LCU admission, median (10,8)12.5 (22-31.81)10.1 (65-13.4)0.01Vital parameters at LCU admission, median (10,8)12.5 (22-31.81)10.1 (65-13.4)0.01Vita parameters at LCU admission, median (10,8)<	Variable	High nutritional risk group (mNUTRIC \geq 5), n = 41, n (%)	Low nutritional risk group (mNUTRIC<5), n = 57, n (%)	p value
Gender Jack Vir (S2.5%) Vir (S2.5%)	Age, median (IQR), years	60 (53–69)	70 (64–75)	<0.001
Male 94 (83%) 47 (82.5%) 0.95 Female 7 (17%) 017.5%) 0 Comorbidities 1 0 0 Diabete 3 (31.7%) 6 (10.5%) 0.02 Diabetes 3 (31.7%) 6 (10.5%) 0.43 Cardiovascular disease 9 (22%) 8 (14%) 0.42 Chronic kideny disease 2 (4.9%) 2 (3.5%) 0.05 Chronic kideny disease 6 (14.6%) 2 (3.5%) 0.07 Malignancy or history of cancer disease 6 (14.6%) 2 (3.5%) 0.01 Respiratory symptoms 41 (100%) 5 (96.5%) 0.01 Cardiovascular symptoms 2 (4.9%) 5 (8.8%) 0.60 Castrointestinal symptoms 7 (17.8) 9 (15.8%) 0.01 Castrointestinal symptoms 7 (2.9) 3 (70–95) 0.33 Respiratory rate, pm 26 (22–35) 8 (3 (63–57.2) 0.09 Vital parameters at (U admission, median (UQR) 2 (2.45–20.1) 8 (7.5–31.4) 0.01 Neutophiles, 10 ⁰ /1. 12 (61–90 <td>Gender</td> <td>. ,</td> <td></td> <td></td>	Gender	. ,		
Female 7 (1%) 10 (17.5%) Comorbidies 21 (36.8%) 0.007 Diabetes 13 (3.7%) 61 (0.5%) 0.027 Obestiy (BMI ≥30 g/m ²) 5 (12.2%) 4 (73) 0.43 Cardinosacular disease 9 (22%) 8 (14%) 0.42 Chronic distructive pulmonary disease 7 (17.1%) 5 (8.8%) 0.35 Chronic distructive pulmonary disease 2 (4.9%) 2 (3.5%) 1.00 Malignancy or history of cancer disease 6 (14.6%) 2 (3.5%) 1.00 Chronic kidney disease 7 (17.8) 5 (95.5%) 1.00 Cardiovascular symptoms 2 (4.9%) 5 (8.9%) 0.09 Gastrointestinal symptoms 7 (17.8) 9 (15.8%) 1.00 Gastrointestinal symptoms 2 (4.9%) 5 (2-9) 1.00 Gastrointestinal symptoms 2 (4.9%) 3 (10-9) 0.33 Meana tertal pressure, mmHg 2 (2-3) 3 (10-9) 0.33 Theory Earlie ters at Eduamission, median (10%) 2 (2-3) 3 (20-3) 0.01 Ustar terta by Mithis b	Male	34 (83%)	47 (82.5%)	0.95
Comonitabilities Image: Constraint of the second sec	Female	7 (17%)	10 (17.5%)	
Hypertension27 (65.9%)21 (36.8%)0.007Diabetes13 (37.8%)6 (10.5%)0.02Obesity (BM ≥30 kg/m ²)5 (12.2%)4 (7%)0.43Cardiovascular disease9 (22%)8 (148)0.35Chronic obstructive pulmonary disease7 (17.1%)5 (8.8%)0.05Chronic kidney disease2 (4.9%)2 (3.5%)0.07Haliganary or history of cancer disease6 (14.6%)2 (3.5%)0.07Initial symptoms8 (92.7%)5 (96.5%)0.01Cardiovascular symptoms2 (4.9%)5 (96.5%)0.09Gastrointestinal symptoms2 (4.9%)5 (96.5%)0.09Gastrointestinal symptoms2 (4.9%)5 (96.5%)0.09Gastrointestinal symptoms2 (4.9%)3 (1-6)0.08Vital parameters at ICU admission, median (0QR)87 (70-107)83 (70-95)0.33Respiratory rate, bpm26 (22-35)28 (22-33)0.07Mean aterial pressure, mmHg26 (10-00)81 (67-90)0.05Laboratory indices at ICU admission, median (0QR)12 (3.63-0.01)87 (5.3-12.4)0.01Neutrophils, x 10 ⁰ /L12 (3.63-0.01)87 (3.3-12.4)0.01Neutrophils, x 10 ⁰ /L12 (3.63-0.01)87 (3.3-12.4)0.01Iupmahoutes, x 10 ⁰ /L12 (3.63-0.69)0.66 (0.46-0.97)0.02Haemoglobin, gidL11 (107-287)280 (21-7.340)0.02Haemoglobin, gidL16 (0.07-2.36)0.01 (0.06 (0.46-0.97)0.02Haemoglobin, gidL16 (0.07-2.36)	Comorbidities			
Diabetes 13 (31,7x) 6 (10.5x) 0.02 Obesity (RM) 230 (kg/m ⁷) 5 (12.2x) 4 (7x) 0.43 Cardiovascular disease 9 (22.5x) 8 (143) 0.43 Chronic obstructive pulmonary disease 7 (17.1x) 5 (8.83) 0.03 Malignancy or history of cancer disease 6 (14.63) 2 (3.5%) 0.07 Initial symptoms 1 (89.5x) 0.07 Respiratory symptoms 41 (1002) 5 (96.5%) 0.01 Cardiovascular symptoms 2 (4.98) 5 (8.85) 0.69 Gastrointestimal symptoms 2 (4.98) 5 (8.5%) 0.09 Heart rate, bp 7 (17.5x) 9 (15.8%) 0.69 Gastrointestimal symptoms 2 (4.98) 5 (2.9) 3 (1-6) 0.89 Heart rate, bp 8 (70–107) 83 (70–90) 0.31 Gastrointestimal symptoms 0.33 Temperature, 'C 36 (8.63–72.2) 36 (3.63–72.3) 0.39 Gastrointestimal symptoms 0.33 Utait parameters at ICU admission, median (IQR) 35 (9.2–21.8) 0.11 (6.5–1.34) 0.01	Hypertension	27 (65.9%)	21 (36.8%)	0.007
Obesity (BMI $\geq 20 kg/m^2$) 5 (12.28) 4 (78) 0.42 Cardiovascular disease 9 (22k) 8 (14k) 0.42 Chronic distructive pulmonary disease 7 (17,13) 5 (8.83) 0.35 Chronic kidney disease 2 (4.93) 2 (3.53) 0.07 Initial symptoms 2 (3.53) 0.07 Initial symptoms 8 (92.73) 5 (8.83) 0.69 Cardiovascular symptoms 2 (4.93) 5 (8.63) 0.69 Gastrointestinal symptoms 2 (4.93) 5 (8.83) 0.69 Gastrointestinal symptoms 2 (4.93) 5 (8.83) 0.69 Gastrointestinal symptoms 2 (4.93) 3 (1-6) 0.08 Vital parameters at ICU admission, median (IQR), days 5 (2-9) 3 (1-6) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean atterial pressure, numblg 25 (63–20.1) 8.7 (53–12.4) 0.01 Neutrophils, x 10 ⁹ /L 135 (92–21.8) 10.1 (65–13.4) 0.01 Neutrophils, x 10 ⁹ /L 0.48 (35–0.69) 0.66 (0.46–0.97) 0.	Diabetes	13 (31.7%)	6 (10.5%)	0.02
Cardiovascular disease 9 (22%) 8 (14%) 0.42 Chronic obstructive pulmonary disease 7 (17,1%) 5 (8.8%) 0.35 Chronic obstructive pulmonary disease 2 (4.9%) 2 (3.5%) 0.07 Malignancy or history of cancer disease 2 (4.9%) 2 (3.5%) 0.07 Initial symptoms 2 (3.5%) 0.91 0.07 Respiratory symptoms 11 (100%) 55 (96.5%) 0.00 Cardiovascular symptoms 7 (17%) 9 (15.8%) 0.00 Castrointestres at ICU admission, median (10R), days 5 (2–9) 3 (1–6) 0.08 Vital parameters at ICU admission, median (10R) 8 (70–107) 8 (70–95) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean arterial pressure, muHig 26 (23–37.2) 28 (22–31) 0.73 Temperature, *C Dadmission, median (10R) U Vital parameter, *C 0.01 White blood cells, x 10 ⁰ /L 1.35 (92–21.8) 10.1 (6.5–13.4) 0.01 Importative, x 10 ⁰ /L 1.25 (15–20.1) 87 (53–12.4) 0.01	Obesity (BMI \geq 30 kg/m ²)	5 (12.2%)	4 (7%)	0.43
Chronic obstructive pulmonary disease 7 (17, 1%) 5 (8.8%) 0.35 Chronic kidney disease 2 (49%) 2 (3.5%) 1.00 Malignarcy or history of cancer disease 6 (14.6%) 2 (3.5%) 0.07 Initial symptoms 8 (92.7%) 5 (8.8%) 0.91 Respiratory symptoms 41 (100%) 5 (8.8%) 0.69 Cardiovascular symptoms 2 (4.9%) 5 (8.8%) 0.69 Gastrointestinal symptoms 7 (17%) 9 (15.8%) 1.00 Pospital LOS before (U dumission, median (10R), days 5 (2–9) 3 (1–6) 0.83 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.73 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.79 Temperature, *C 36 (36–37.2) 36 (36–37.5) 0.09 Laboratory indices at LO admission, median (IQR) 13 (9–21.8) 10 (65–13.4) 0.01 Neutrophils, x 10 ⁹ /L 12 (8 (8–20.1) 87 (53–12.4) 0.01 Neutrophils, x 10 ⁹ /L 0.48 (0.35–0.69) 0.66 (0.46–0.97) 0.50 Haemoglobin, gidl	Cardiovascular disease	9 (22%)	8 (14%)	0.42
Chronic kidney disease 2 (4.9%) 2 (3.5%) 1.00 Malignancy or history of cancer disease 6 (14.6%) 2 (3.5%) 0.07 Initial symptoms 8 (92.7%) 51 (89.5%) 0.91 Respiratory symptoms 41 (100%) 55 (96.5%) 1.00 Cardiovascular symptoms 2 (4.9%) 5 (8.8%) 0.69 Gastrointestrial symptoms 7 (17%) 9 (15.8%) 1.00 Heart rate, hopm 88 (70–107) 83 (70–95) 0.33 Respiratory rate, hopm 26 (22–33) 28 (22–33) 0.78 Mean arterial pressure, mmHg 72 (61–90) 81 (67–90) 0.33 Temperature, *C 36.8 (36–37.2) 369 (36.5–37.5) 0.90 Laboratory indices at ICU admission, median (IQR) 125 (82–21.8) 10.1 (6.5–13.4) 0.01 Neutrophils, x 10 ⁰ /L 125 (85–20.1) 8.7 (53–12.4) 0.01 Iypphocytes, x 10 ⁰ /L 125 (85–20.1) 8.7 (53–12.4) 0.01 Iypphocytes, x 10 ⁰ /L 125 (85–20.1) 8.7 (53–12.4) 0.01 Iyphocytes, x 10 ⁰ /L 126 (92–21.8)<	Chronic obstructive pulmonary disease	7 (17.1%)	5 (8.8%)	0.35
Mailgnancy or history of cancer disease 6 (14.6%) 2 (3.5%) 0.07 Initial symptoms	Chronic kidney disease	2 (4.9%)	2 (3.5%)	1.00
Initial symptoms Initial symptoms <thinitial symptoms<="" th=""> <thinitial symptom<="" td="" th<=""><td>Malignancy or history of cancer disease</td><td>6 (14.6%)</td><td>2 (3.5%)</td><td>0.07</td></thinitial></thinitial>	Malignancy or history of cancer disease	6 (14.6%)	2 (3.5%)	0.07
Fever 38 (92.7x) 51 (89.5x) 0.91 Respiratory symptoms 41 (100x) 55 (96.5x) 1.00 Cardiovascular symptoms 2 (4.9x) 5 (8.8x) 0.69 Gastrointestinal symptoms 7 (17x) 9 (15.8x) 1.00 Hospital LOS before ICU admission, median (IQR) 7 (17x) 9 (15.8x) 0.08 Vital parameters at ICU admission, median (IQR) 88 (70–107) 83 (70–95) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean arterial pressure, mmHg 72 (61–90) 81 (67–90) 0.33 Temperature, °C 36.8 (36–37.2) 36.9 (36.5–37.5) 0.09 Laboratory indices at ICU admission, median (IQR) 12.5 (8.5–20.1) 87.(5–312.4) 0.01 Neutrophits, 10 ⁹ /L 12.5 (8.5–20.1) 87.(5–3-12.4) 0.01 Iymphocytes, x 10 ⁹ /L 0.48 (035–0.69) 0.66 (0.46–0.97) 0.55 Platelets, x 10 ⁹ /L 12.6 (8.5–2.18) 10.1 (6.5–13.4) 0.01 Iymphocytes, x 10 ⁹ /L 14.6 (0.07–2.36) 0.71 (0.64–1.12) 0.32 Pla	Initial symptoms			
Respiratory symptoms 41 (1002) 55 (96.5%) 1.00 Cardiovascular symptoms 2 (4.9%) 5 (8.8%) 0.69 Gastrointestinal symptoms 7 (17%) 9 (15.8%) 1.00 Hospital LOS before ICU admission, median (IQR), days 5 (2–9) 3 (1–6) 0.88 Vital parameters at ICU admission, median (IQR) 88 (70–107) 83 (70–95) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean arterial pressure, mmHg 72 (61–90) 81 (67–90) 0.33 Temperature, *C 368 (36–37.2) 86 (36–37.5) 0.01 Laboratory indices at ICU admission, median (IQR) 125 (85–20.1) 8.7 (5.3–12.4) 0.01 Lymphorytes, x 10 ⁹ /L 125 (85–20.1) 8.7 (5.3–12.4) 0.02 Haemoglobin, g/dL 118 (10.7–13.2) 122 (11–13.4) 0.25 Haemoglobin, g/dL 118 (10.7–13.2) 102 (16–4–11.2) 0.001 Urea, mg/dL 71 (50–11.2) 50 (33–63) 0.001 Creatinie, mg/dL 108 (0.79–1.31) 0.75 (0.64–1.17) 0.02 Procalciton	Fever	38 (92.7%)	51 (89.5%)	0.91
Cardiovascular symptoms 2 (4.9x) 5 (8.8x) 0.69 Gastrointestinal symptoms 7 (17%) 9 (15.8x) 1.00 Hospital LOS before ICU admission, median (IQR), days 5 (2–9) 3 (1–6) 0.08 Vital parameters at ICU admission, median (IQR) Heart rate, bpm 88 (70–107) 83 (70–95) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean arterial pressure, mmHg 72 (61–90) 81 (67–90) 0.33 Temperature, *C 36.8 (36–37.2) 36.9 (36.5–37.5) 0.01 White blood cells, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Neutrophils, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Lymphocytes, x 10 ⁹ /L 11.8 (10.7–13.2) 12.2 (11–13.4) 0.25 Platentets, x 10 ⁹ /L 211 (179–287) 280 (217–340) 0.02 Total bilirubin, mg/dL 0.98 (0.79–1.31) 0.75 (0.64–1.12) 0.001 Urea, mg/dL 160 (0.77–2.36) 0.20 (3.69–16.87) 0.04 Glucose, mg/dL	Respiratory symptoms	41 (100%)	55 (96.5%)	1.00
Gastrointestinal symptoms 7 (17%) 9 (15.8%) 1.00 Hospital LOS before LOL admission, median (IQR), days 7 (17%) 9 (15.8%) 1.00 Hospital LOS before LOL admission, median (IQR) 0.00 0.00 Vital parameters at LOL admission, median (IQR) 88 (70–107) 83 (70–95) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean atterial pressure, mmHg 7 (16–90) 81 (67–90) 0.33 Temperature, °C 368 (36–37.2) 36 (36–37.5) 0.09 Laboratory indices at LO admission, median (IQR) 13.5 (92–21.8) 10.1 (65–13.4) 0.01 Neutrophils, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Neutrophils, x 10 ⁹ /L 0.48 (0.35–069) 0.66 (0.46–0.97) 0.05 Haemoglobin, g/dL 11.8 (10.7–13.2) 12.2 (11–13.4) 0.25 Platelets, x 10 ⁹ /L 21.0 (0.01 10.0 (0.64–1.12) 0.001 Urgmboryter, sx 10.9 (L 12.0 (0.11 10.0 (0.64–1.12) 0.001 Urgen, g/dL 7 (15.0–12) 50 (33–63) 0.001 <	Cardiovascular symptoms	2 (4.9%)	5 (8.8%)	0.69
Hospital LOS before ICU admission, median (IQR), days 5 (2-9) 3 (1-6) 0.08 Vital parameters at ICU admission, median (IQR) 0.33 Heart rate, bpm 88 (70-107) 83 (70-95) 28 (22-33) 0.78 Mean arterial pressure, mHg 26 (22-35) 28 (22-33) 0.33 Temperature, *C 36.8 (36-37.2) 36.9 (36.5-37.5) 0.09 Laboratory indices at ICU admission, median (IQR) 0.01 White blood cells, x 10 ⁹ /L 12.5 (8.5-20.1) 8.7 (5.3-12.4) 0.01 Neutrophis, x 10 ⁹ /L 12.5 (8.5-20.1) 8.7 (5.3-12.4) 0.01 Lymphocytes, x 10 ⁹ /L 11.8 (10.7-13.2) 12.2 (11-13.4) 0.25 Platelets, x 10 ⁹ /L 211 (179-287) 280 (217-340) 0.02 Urea, mg/dL 71 (50-112) 50 (33-63) 0.001 Urea, mg/dL 71 (50-112) 50 (33-63) 0.001 Urea, mg/dL 71 (50-112) 50 (33-63) 0.001 Gescore, median (UQR) 6 (4-7) 3 (2-4) -0.001	Gastrointestinal symptoms	7 (17%)	9 (15.8%)	1.00
Vital parameters at ICU admission, median (lQR) 88 (70–107) 83 (70–95) 0.33 Heart rate, bpm 88 (70–107) 83 (70–95) 0.33 Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean arterial pressure, mmHg 72 (61–90) 81 (67–90) 0.33 Temperature, *C 36.8 (36–37.2) 36.9 (36.5–37.5) 0.09 Laboratory indices at ICU admission, median (IQR) 13.5 (9.2–21.8) 10.1 (6.5–13.4) 0.01 Neutrophils, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Lymphocytes, x 10 ⁹ /L 12.8 (8.035–0.69) 0.66 (0.46–0.97) 0.05 Haemoglobin, g/dL 11.8 (10.7–13.2) 12.2 (11–13.4) 0.25 Platelets, x 10 ⁹ /L 12.60 (0.77–2.36) 0.71 (0.64–1.12) 0.001 Urea, mg/dL 71 (50–112) 50 (33–63) 0.001 Urea, mg/dL 72 (51–32.4) 0.02 71 (0.64–1.12) 0.001 Urea, mg/dL 71 (50–112) 50 (33–63) 0.001 0.02 Procalcitonin, ng/mL 17.25 (9.3–23.6) 10.20 (3.69–16.87) 0.04 <td>Hospital LOS before ICU admission, median (IQR), days</td> <td>5 (2-9)</td> <td>3 (1-6)</td> <td>0.08</td>	Hospital LOS before ICU admission, median (IQR), days	5 (2-9)	3 (1-6)	0.08
Heart rate, bpm88 (70–107)83 (70–95)0.33Respiratory rate, bpm26 (22–35)28 (22–33)0.78Mean arterial pressue, mmHg25 (61–90)81 (67–90)0.33Temperature, °C36.8 (36–37.2)36.9 (36.5–37.5)0.09Laboratory indices at ICU admission, median (IQR)u0.01White blood cells, x 10 ⁹ /L13.5 (9.2–21.8)10.1 (6.5–13.4)0.01Neutrophils, x 10 ⁹ /L0.48 (0.35–069)0.66 (0.46–0.97)0.05Haemoglobin, g/dL11.8 (10.7–13.2)12.2 (11–13.4)0.25Platelets, x 10 ⁹ /L211 (179–287)280 (217–340)0.02Total bilirubin, mg/dL1.60 (0.77–2.36)0.71 (0.64–1.12)0.001Urea, mg/dL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/nL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/nL13.6 (1.4–17)0.33 (0.11–0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3–22.6)10.20 (3.69–16.87)0.04Glucose, mg/dL169 (124–201)130 (120–151)0.14GCS score, median (IQR)6 (4–7)3 (2–4)<0.001	Vital parameters at ICU admission, median (IQR)		· · · ·	
Respiratory rate, bpm 26 (22–35) 28 (22–33) 0.78 Mean arterial pressure, mmHg 72 (61–90) 81 (67–90) 0.33 Temperature, *C 368 (36–37.2) 36.9 (36.5–37.5) 0.09 Laboratory indices at ICU admission, median (IQR) 13.5 (9.2–21.8) 10.1 (6.5–13.4) 0.01 White blood cells, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Lymphocytes, x 10 ⁹ /L 0.48 (0.35–0.69) 0.66 (0.46–0.97) 0.05 Haemoglobin, g/dL 11.8 (10.7–13.2) 12.2 (11–13.4) 0.25 Platelets, x 10 ⁹ /L 211 (79–287) 280 (217–340) 0.02 Total bilirubin, mg/dL 1.60 (0.77–2.36) 0.71 (0.64–1.12) 0.001 Urea, mg/dL 0.98 (0.79–1.31) 0.75 (0.64–1.17) 0.02 Creatinine, mg/dL 0.98 (0.79–1.31) 0.75 (0.64–1.17) 0.02 Procalcitonin, ng/mL 0.86 (0.21–1.77) 0.33 (0.11–0.91) 0.04 High-sensitivity C-reactive protein, mg/L 17.25 (9.3–23.6) 10.20 (3.69–16.87) 0.001 Greatinine, mg/dL 169 (124–201) 130 (120–151) 0	Heart rate, bpm	88 (70-107)	83 (70-95)	0.33
Mean arterial pressure, mmHg 72 (61-90) 81 (67-90) 0.33 Temperature, °C 36.8 (36-37.2) 36.9 (36.5-37.5) 0.09 Laboratory indices at ICU admission, median (IQR) 13.5 (9.2-21.8) 10.1 (6.5-13.4) 0.01 Neutrophils, x 10 ⁹ /L 12.5 (8.5-20.1) 8.7 (5.3-12.4) 0.01 Neutrophils, x 10 ⁹ /L 0.48 (0.35-0.69) 0.66 (0.46-0.97) 0.05 Haemoglobin, g/dL 11.8 (10.7-13.2) 12.2 (11-13.4) 0.25 Platelets, x 10 ⁹ /L 211 (179-287) 280 (217-340) 0.02 Urea, mg/dL 160 (0.79-2.36) 0.71 (0.64-1.12) 0.001 Urea, mg/dL 71 (50-112) 50 (33-63) 0.001 Urea, mg/dL 0.98 (0.79-1.31) 0.75 (0.64-1.17) 0.02 Procalcitonin, ng/mL 0.86 (0.21-1.77) 0.33 (0.11-0.91) 0.04 Glucose, mg/dL 169 (124-201) 130 (120-151) 0.14 GCS score, median (IQR) 6 (4-7) 3 (2-4) 0.001 Juritorin of mechanical ventilation, median (IQR), days 9 (5-17) 8 (2-1) 0.035 OPa	Respiratory rate, bpm	26 (22-35)	28 (22-33)	0.78
Temperature, ${}^{\circ}C$ 36.8 (36–37.2)36.9 (36.5–37.5)0.09Laboratory indices at ICU admission, median (IQR) $($ White blood cells, x 10 ⁹ /L13.5 (9.2–21.8)10.1 (6.5–13.4)0.01Neutrophils, x 10 ⁹ /L12.5 (8.5–20.1)8.7 (5.3–12.4)0.01Lymphocytes, x 10 ⁹ /L0.48 (0.35–0.69)0.66 (0.46–0.97)0.05Haemoglobin, g/dL11.8 (107–13.2)12.2 (11–13.4)0.25Platelets, x 10 ⁹ /L211 (179–287)280 (217–340)0.02Total bilirubin, mg/dL1.60 (0.77–2.36)0.71 (0.64–1.12)0.001Urea, mg/dL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/mL0.98 (0.21–1.77)0.33 (0.11–0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3–23.6)10.20 (3.69–16.87)0.04GCs core, median (IQR)6 (4–7)3 (2–4)<0.001	Mean arterial pressure, mmHg	72 (61–90)	81 (67–90)	0.33
Laboratory indices at ICU admission, median (IQR) No. White blood cells, x 10 ⁹ /L 13.5 (9.2–21.8) 10.1 (6.5–13.4) 0.01 Neutrophils, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Lymphocytes, x 10 ⁹ /L 0.48 (0.35–0.69) 0.66 (0.46–0.97) 0.05 Haemoglobin, g/dL 11.8 (10.7–13.2) 12.2 (11–13.4) 0.25 Platelets, x 10 ⁹ /L 211 (179–287) 280 (217–340) 0.001 Urea, mg/dL 1.60 (0.77–2.36) 0.71 (0.64–1.12) 0.001 Urea, mg/dL 0.98 (0.79–1.31) 0.75 (0.64–1.17) 0.02 Procalcitonin, ng/mL 0.86 (0.21–1.77) 0.33 (0.11–0.91) 0.04 High-sensitivity C-reactive protein, mg/L 17.25 (9.3–23.6) 10.20 (3.69–16.87) 0.04 Glucose, mg/dL 166 (124–201) 130 (120–151) 0.14 GCS score, median (IQR) 6 (4–7) 3 (2–4) <0.001	Temperature, °C	36.8 (36-37.2)	36.9 (36.5-37.5)	0.09
White bod cells, x $10^9/L$ 13.5 (9.2–21.8)10.1 (6.5–13.4)0.01Neutrophils, x $10^9/L$ 12.5 (85–20.1)8.7 (5.3–12.4)0.01Lymphocytes, x $10^9/L$ 0.48 (0.35–0.69)0.66 (0.46–0.97)0.05Haemoglobin, g/dL11.8 (10.7–13.2)12.2 (11–13.4)0.25Platelets, x $10^9/L$ 211 (179–287)280 (217–340)0.02Total bilirubin, mg/dL1.60 (0.77–2.36)0.71 (0.64–1.12)0.001Urea, mg/dL71 (50–112)50 (33–63)0.001Creatinine, mg/dL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/mL0.86 (0.21–1.77)0.33 (0.11–0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3–23.6)10.20 (3.69–16.87)0.04Glucose, mg/dL169 (124–201)130 (120–151)0.14GCS score, median (IQR)6 (4–7)3 (2–4)<0.001	Laboratory indices at ICU admission, median (IOR)			
Neutrophils, x 10 ⁹ /L 12.5 (8.5–20.1) 8.7 (5.3–12.4) 0.01 Lymphocytes, x 10 ⁹ /L 0.48 (0.35–0.69) 0.66 (0.46–0.97) 0.05 Haemoglobin, g/dL 11.8 (10.7–13.2) 12.2 (11–13.4) 0.25 Platelets, x 10 ⁹ /L 211 (179–287) 280 (217–340) 0.02 Total bilirubin, mg/dL 1.60 (0.77–2.36) 0.71 (0.64–1.12) 0.001 Urea, mg/dL 71 (50–112) 50 (33–63) 0.02 Creatinine, mg/dL 0.98 (0.79–1.31) 0.75 (0.64–1.17) 0.02 Procalcitonin, ng/mL 0.86 (0.21–1.77) 0.33 (0.11–0.91) 0.04 Glucose, mg/dL 17.25 (9.3–23.6) 10.20 (3.69–16.87) 0.04 Glucose, mg/dL 169 (124–201) 130 (120–151) 0.14 GCS score, median (IQR) 6 (4–7) 3 (2–4) <0.001	White blood cells, x $10^9/L$	13.5 (9.2-21.8)	10.1 (6.5–13.4)	0.01
Lymphocytes, x 10 ⁹ /L0.48 (0.35-0.69)0.66 (0.46-0.97)0.05Haemoglobin, g/dL11.8 (10.7-13.2)12.2 (11-13.4)0.25Platelets, x 10 ⁹ /L211 (179-287)280 (217-340)0.02Total bilirubin, mg/dL1.60 (0.77-2.36)0.71 (0.64-1.12)0.001Urea, mg/dL71 (50-112)50 (33-63)0.001Creatinine, mg/dL0.98 (0.79-1.31)0.75 (0.64-1.17)0.02Procalcitonin, ng/mL0.86 (0.21-1.77)0.33 (0.11-0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3-23.6)10.20 (3.69-16.87)0.04Glucose, mg/dL169 (124-201)130 (120-151)0.14GCS score, median (IQR)6 (4-7)3 (2-4)<0.001	Neutrophils, x 10 ⁹ /L	12.5 (8.5-20.1)	8.7 (5.3–12.4)	0.01
Haemoglobin, g/dL $11.8 (10.7-13.2)$ $12.2 (11-13.4)$ 0.25 Platelets, x $10^9/L$ $211 (179-287)$ $280 (217-340)$ 0.02 Total bilirubin, mg/dL $1.60 (0.77-2.36)$ $0.71 (0.64-1.12)$ 0.001 Urea, mg/dL $0.98 (0.79-1.31)$ $0.75 (0.64-1.17)$ 0.02 Procalcitonin, ng/mL $0.98 (0.79-1.31)$ $0.75 (0.64-1.17)$ 0.02 Procalcitonin, ng/mL $0.86 (0.21-1.77)$ $0.33 (0.11-0.91)$ 0.04 High-sensitivity C-reactive protein, mg/L $17.25 (9.3-23.6)$ $10.20 (3.69-16.87)$ 0.04 Glucose, mg/dl $13 (4-14)$ $15 (14-15)$ 0.003 SOFA score, median (IQR) $6 (4-7)$ $3 (2-4)$ <0.001 APACHE II score, median (IQR) $6 (4-7)$ $3 (2-4)$ <0.001 Duration of mechanical ventilation, median (IQR), days $9 (5-17)$ $8.5 (5-11)$ 0.44 Treatments in ICU $(CRRT)$ $1(2.4\%)$ $1(1.8\%)$ 0.035 Non-invasive ventilation (C-PAP, bi-level) 0 $3 (5.3\%)$ 0.15 Invasive mechanical ventilation $41 (100\%)$ $54 (94.7\%)$ 0.38 Prone positioning $20 (48.8\%)$ $24 (42.1\%)$ 0.38 Prone positioning $20 (48.8\%)$ $24 (42.1\%)$ 0.001	Lymphocytes, x $10^9/L$	0.48 (0.35-0.69)	0.66 (0.46-0.97)	0.05
Platelets, x 10 ⁹ /L 211 (179–287) 280 (217–340) 0.02 Total bilirubin, mg/dL 1.60 (0.77–2.36) 0.71 (0.64–1.12) 0.001 Urea, mg/dL 71 (50–112) 50 (33–63) 0.001 Creatinine, mg/dL 0.98 (0.79–1.31) 0.75 (0.64–1.17) 0.02 Procalcitonin, ng/mL 0.86 (0.21–1.77) 0.33 (0.11–0.91) 0.04 High-sensitivity C-reactive protein, mg/L 17.25 (9.3–23.6) 10.20 (3.69–16.87) 0.04 Glucose, mg/dL 169 (124–201) 130 (120–151) 0.14 GCS score, median (IQR) 13 (4–14) 15 (14–15) 0.003 SOFA score, median (IQR) 27 (24–29) 15 (12–24) <0.001	Haemoglobin, g/dL	11.8 (10.7–13.2)	12.2 (11–13.4)	0.25
Total bilirubin, mg/dL1.60 (0.77–2.36)0.71 (0.64–1.12)0.001Urea, mg/dL71 (50–112)50 (33–63)0.001Creatinine, mg/dL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/mL0.86 (0.21–1.77)0.33 (0.11–0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3–23.6)10.20 (3.69–16.87)0.04Glucose, mg/dL169 (124–201)130 (120–151)0.14GCS score, median (IQR)13 (4–14)15 (14–15)0.003SOFA score, median (IQR)6 (4–7)3 (2–4)<0.001	Platelets, x 10 ⁹ /L	211 (179–287)	280 (217-340)	0.02
Urea, mg/dL71 (50–112)50 (33–63)0.001Creatinine, mg/dL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/mL0.86 (0.21–1.77)0.33 (0.11–0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3–23.6)10.20 (3.69–16.87)0.04Glucose, mg/dL169 (124–201)130 (120–151)0.14CCS score, median (IQR)13 (4–14)15 (14–15)0.003SOFA score, median (IQR)6 (4–7)3 (2–4)<0.001	Total bilirubin, mg/dL	1.60 (0.77-2.36)	0.71 (0.64–1.12)	0.001
Creatinine, mg/dL0.98 (0.79–1.31)0.75 (0.64–1.17)0.02Procalcitonin, ng/mL0.86 (0.21–1.77)0.33 (0.11–0.91)0.04High-sensitivity C-reactive protein, mg/L17.25 (9.3–23.6)10.20 (3.69–16.87)0.04Glucose, mg/dL169 (124–201)130 (120–151)0.14GCS score, median (IQR)13 (4–14)15 (14–15)0.003SOFA score, median (IQR)6 (4–7)3 (2–4)<0.001	Urea, mg/dL	71 (50–112)	50 (33-63)	0.001
Procalcitonin, ng/mL 0.86 (0.21-1.77) 0.33 (0.11-0.91) 0.04 High-sensitivity C-reactive protein, mg/L 17.25 (9.3-23.6) 10.20 (3.69-16.87) 0.04 Glucose, mg/dL 169 (124-201) 130 (120-151) 0.14 GCS score , median (IQR) 13 (4-14) 15 (14-15) 0.003 SOFA score , median (IQR) 6 (4-7) 3 (2-4) <0.001	Creatinine, mg/dL	0.98 (0.79-1.31)	0.75 (0.64-1.17)	0.02
High-sensitivity C-reactive protein, mg/L 17.25 (9.3–23.6) 10.20 (3.69–16.87) 0.04 Glucose, mg/dL 169 (124–201) 130 (120–151) 0.14 GCS score, median (IQR) 13 (4–14) 15 (14–15) 0.003 SOFA score, median (IQR) 6 (4–7) 3 (2–4) <0.001	Procalcitonin, ng/mL	0.86 (0.21-1.77)	0.33 (0.11-0.91)	0.04
Glucose, mg/dL 169 (124–201) 130 (120–151) 0.14 GCS score, median (IQR) 13 (4–14) 15 (14–15) 0.003 SOFA score, median (IQR) 6 (4–7) 3 (2–4) <0.001	High-sensitivity C-reactive protein, mg/L	17.25 (9.3–23.6)	10.20 (3.69–16.87)	0.04
GCS score, median (IQR) 13 (4–14) 15 (14–15) 0.003 SOFA score, median (IQR) 6 (4–7) 3 (2–4) <0.001	Glucose, mg/dL	169 (124–201)	130 (120–151)	0.14
SOFA score, median (IQR) 6 (4–7) 3 (2–4) <0.001 APACHE II score, median (IQR) 27 (24–29) 15 (12–24) <0.001	GCS score, median (IQR)	13 (4-14)	15 (14–15)	0.003
APACHE II score, median (IQR) 27 (24–29) 15 (12–24) <0.001	SOFA score, median (IOR)	6 (4-7)	3 (2-4)	< 0.001
Duration of mechanical ventilation, median (IQR), days 9 (5–17) 8.5 (5–11) 0.44 Treatments in ICU 1 1.2.4%) 1 (1.8%) 1.00 Vasopressors 27 (65.9%) 28 (49.1%) 0.035 Non-invasive ventilation (C-PAP, bi-level) 0 3 (5.3%) 0.15 Invasive mechanical ventilation 41 (100%) 54 (94.7%) 0.38 Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	APACHE II score, median (IQR)	27 (24-29)	15 (12-24)	< 0.001
Treatments in ICU 1 (2.4%) 1 (1.8%) 1.00 CRRT 1 (2.4%) 1 (1.8%) 0.035 Vasopressors 27 (65.9%) 28 (49.1%) 0.035 Non-invasive ventilation (C-PAP, bi-level) 0 3 (5.3%) 0.15 Invasive mechanical ventilation 41 (100%) 54 (94.7%) 0.38 Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	Duration of mechanical ventilation, median (IOR), days	9 (5-17)	8.5 (5-11)	0.44
CRRT 1 (2.4%) 1 (1.8%) 1.00 Vasopressors 27 (65.9%) 28 (49.1%) 0.035 Non-invasive ventilation (C-PAP, bi-level) 0 3 (5.3%) 0.15 Invasive mechanical ventilation 41 (100%) 54 (94.7%) 0.38 Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	Treatments in ICU			
Vasopressors 27 (65.9%) 28 (49.1%) 0.035 Non-invasive ventilation (C-PAP, bi-level) 0 3 (5.3%) 0.15 Invasive mechanical ventilation 41 (100%) 54 (94.7%) 0.38 Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	CRRT	1 (2.4%)	1 (1.8%)	1.00
Non-invasive ventilation (C-PAP, bi-level) 0 3 (5.3%) 0.15 Invasive mechanical ventilation 41 (100%) 54 (94.7%) 0.38 Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	Vasopressors	27 (65.9%)	28 (49.1%)	0.035
Invasive mechanical ventilation 41 (100%) 54 (94.7%) 0.38 Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	Non-invasive ventilation (C-PAP, bi-level)	0	3 (5.3%)	0.15
Prone positioning 20 (48.8%) 24 (42.1%) 0.49 28-day mortality 33 (80.5%) 12 (21.1%) <0.001	Invasive mechanical ventilation	41 (100%)	54 (94.7%)	0.38
28-day mortality 33 (80.5%) 12 (21.1%) <0.001	Prone positioning	20 (48.8%)	24 (42.1%)	0.49
	28-day mortality	33 (80.5%)	12 (21.1%)	< 0.001

Table 3

Multivariable Cox proportional hazards regression analysis of factors associated with mortality.

Variable	HR	95% CI	p value	Optimism adjusted HR	Optimism adjusted 95% Cl
$mNUTRIC \ge 5$	2.64	1.20-5.83	0.02	2.38	1.08-5.25
High-sensitivity C-reactive protein, mg/L	1.13	1.12-1.19	0.005	1.02	1.02-1.07
Neutrophils, x 10 ⁹ /L	1.05	0.99-1.11	0.12	0.95	0.90-1.00

was recently confirmed as a useful tool to predict mortality of ICU COVID-19 patients [13,39–44]. On the contrary, Liberti et al., reported a low discriminative ability of NUTRIC and mNUTRIC scores to predict ICU mortality of COVID-19 patients [45]. Some possible reasons for these different results can be found in the limited number of patients included and no covariates adjustment along with very short interval between hospital and ICU admission compared to other studies.

To our knowledge, our study is the first internal validated model with the use of mNUTRIC score to predict 28-day mortality in critically ill COVID-19 patients. Moreover, the use of mNUTRIC improved the outcome prediction ability compared to our previously published study [46]. However, even if our model showed a good discriminatory accuracy for 28-day mortality prediction in critically ill COVID-19 patients, more prospective studies are needed to evaluate the role of mNUTRIC and how to reduce malnutrition onset in these patients.

This study has several limitations. First, it is a single centre retrospective study during a pandemic that heavily affect medical resources. Therefore, some data might present inaccuracies and bias.



Fig. 2. Bootstrap estimate of calibration accuracy for 28-day mortality estimates from the final Cox model, using adaptive linear spline hazard regression. The line nearer the ideal line corresponds to apparent predictive accuracy. The blue curve corresponds to bootstrap-corrected estimates.

A limited number of subjects were enrolled, however this issue is guite counteracted by the internal validation process. Nutritional risk assessment was performed at ICU admission and no dynamic evaluations were provided. Consequently, we cannot infer the role of nutritional support in terms of outcome and if the nutritional risk changed over time. We did not use the NRS-2002 score to evaluate nutritional status since it was not specifically developed for ICU patients. Moreover, as it was recently reported by Achean et al., mNUTRIC score was able to with higher prognostic accuracy compared to NRS-2002 for early mortality prediction in ICU patients affected by severe pneumonia [41]. Another major problem is the lack of albumin and pre-albumin levels or others rapidturnover visceral proteins or muscle mass assessment in our patients as classical laboratory indexes for nutritional assessment [47,48]. These data were available in only a small amount of patients without reaching the required minimum sample size to be analysed. However, albumin and pre-albumin levels are mainly indicators of the inflammatory status and probably they are poor reliable nutritional indexes in presence of inflammatory state induced by SARS-CoV-2. Another major limit of our study is the lack of body composition parameters such as skeletal muscle index, visceral adiposity and sarcopenic obesity with a possible high predictive value for mortality in ICU patients. The principal aim of our study was to simply investigate the role of different clinical risk scores (mNUTRIC, SOFA and APACHE II) to predict 28-day mortality in critically ill COVID-19 patients admitted to ICU and at the time of writing this paper all the patients concluded the follow-up period.

Further analyses are certainly needed to confirm these results and to evaluate the role of mNUTRIC to predict complications such as secondary infection, organ failure or thrombosis during the ICU length of stay of critically ill COVID-19 patients.

5. Conclusions

A high nutritional risk (mNUTRIC \geq 5 points) was found in 41.8% of critically ill COVID-19 patients admitted to ICU and this data correlate with higher negative outcome prediction and observed deaths. In our internal validated multivariable model mNUTRIC \geq 5 along with CRP values were independent predictors of 28-day mortality. When compared to other prediction score for mortality (SOFA and APACHE-II), high mNUTRIC showed the highest sensitivity and specificity for 28-day mortality of critically ill COVID-19 patients admitted to ICU. Nutritional risk assessment is essential in critically ill COVID-19 patients to provide appropriate nutrition support.

Future studies with increased patients number and longer follow-up are needed to confirm our findings.

Ethics approval and consent to participate

This study was approved by the Ethical Committees of Area Vasta Emilia Nord; protocol: 1066/2020/OSS*/AUSLPC; date of approval: (October 20, 2020).

Consent for publication

Not applicable.

Availability of data and materials

The dataset used and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

No funding was provided for this study from any source and no financial benefits were provided to the authors. No previous presentation of the research, manuscript, or abstract in any form has occurred.

Author contribution

MLGL, EM and MB collected the epidemiological and clinical data. LMLG performed the statistical analysis and drafted the manuscript. NM and MZ revised the final manuscript and contributed substantially to the study design.

Declaration of competing interest

The authors certify that they have no affiliation with, or involvement in any organization or entity with any financial or non-financial interest in the subject matter discussed in this manuscript.

Acknowledgements

The Authors thank all the doctors, residents and nurses directly involved in the management of these patients during this pandemic with such a difficult health crisis. We thank John Shaw for English revision and editing and Lorenzo Bottazzi for data collection support.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.clnesp.2022.02.014.

Abbreviations

mNUTRIC COVID-19	modified Nutrition Risk in the Critically ill score Coronavirus Disease 2019
ICU	intensive care unit
APACHE II	Acute Physiology and Chronic Health Disease
	Classification System II
SOFA	Sequential Organ Failure Assessment
GCS	Glasgow Coma Scale
CRP	C-reactive protein
AUC	receiving operating characteristic
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
EN	enteral nutrition
TPN	total parenteral nutrition
PN	parenteral nutrition
IQR	Interquartile Range
BMI	body mass index
HR	hazard ratio
LOS	Length of Stay
C-PAP	continuous positive airway pressure
CRRT	continuous renal replacement therapy

References

- Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 implications for the health care system. N Engl J Med 2020 Oct 8;383(15):1483–8. https://doi.org/ 10.1056/NEJMsb2021088. Epub 2020 Jul 22. Erratum in: N Engl J Med. 2020 Jul 23;: PMID: 32706956.
- [2] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 2020;81(2):16-25. https://doi.org/10.1016/j.jinf.2020.04.021.
- [3] Alberda C, Gramlich L, Jones N, Jeejeebhoy K, Day AG, Dhaliwal R, et al. The relationship between nutritional intake and clinical outcomes in critically ill patients: results of an international multicenter observational study. Intensive Care Med 2009 Oct;35(10):1728–37. https://doi.org/10.1007/s00134-009-1567-4.
- [4] Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr Nature Publishing Group 2020;74:871–5.
- [5] Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr 2020;39:1631–8.
- [6] Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019 Feb;38(1):48–79. https://doi.org/10.1016/j.clnu.2018.08.037. Epub 2018 Sep 29. PMID: 30348463.
- [7] McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Society of critical care medicine; American society for parenteral and enteral nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: society of critical care medicine (SCCM) and American society for parenteral and enteral nutrition (A.S.P.E.N.). J Parenter Enteral Nutr 2016;40:159–211.
- [8] Kilıç YA. Intensive care scoring systems: why, how, where we are? J Med Surg Intensive Care Med 2002;2:26–31.
- [9] Kumar S, Gattani SC, Baheti AH, Dubey A. Comparison of the performance of Apache II, SOFA, and mNUTRIC scoring systems in critically ill patients: a 2year cross-sectional study. Indian J Crit Care Med 2020 Nov;24(11): 1057–61. https://doi.org/10.5005/jp-journals-10071-23549. PMID: 3338 4511; PMCID: PMC7751038.

- [10] Rahman A, Hasan RM, Agarwala R, Martin C, Day AG, Heyland DK. Identifying critically-ill patients who will benefit most from nutritional therapy: further validation of the "modified NUTRIC" nutritional risk assessment tool. Clin Nutr 2016;35(1):158e62.
- [11] Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302: 1872–9. https://doi.org/10.1001/jama.2009.1496.
- [12] SCCM. SSC COVID-19 guidelines. https://www.sccm.org/SurvivingSepsis Campaign/Guidelines/COVID-19.
- [13] Zhang P, He Z, Yu G, Peng D, Feng Y, Ling J, et al. The modified NUTRIC score can be used for nutritional risk assessment as well as prognosis prediction in critically ill COVID-19 patients. Clin Nutr 2021 Feb;40(2):534-41. https:// doi.org/10.1016/j.clnu.2020.05.051. Epub 2020 Jun 5. PMID: 32527576; PMCID: PMC7273137.
- [14] Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med 1990;9:1303–25. https://doi.org/10.1002/sim.4780091109.
- [15] Harrell FE. Regression modeling strategies with applications to linear models, logistic regression and survival analysis. New York: Springer; 2001. p. 1–330.
- [16] Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015;162:W1-73. https://doi.org/10.7326/M14-0698.
- [17] Perkins NJ, Schisterman EF. The Youden index and the optimal cut-point corrected for measurement error. Biom J 2005;47(4):428–41.
- [18] Rouget A, Vardon-Bounes F, Lorber P, Vavasseur A, Marion O, Marcheix B, et al. Prevalence of malnutrition IN COVID-19 inpatients: the NUTRICOV study. Br J Nutr 2020 Dec 21:1–24. https://doi.org/10.1017/S0007114520005127. Epub ahead of print. PMID: 33342449.
- [19] Yu PJ, Cassiere H, DeRosa S, Bocchieri K, Yar S, Hartman A. Hypermetabolism and coronavirus disease 2019. JPEN - J Parenter Enter Nutr 2020 Sep;44(7): 1234–6. https://doi.org/10.1002/jpen.1948. Epub 2020 Jul 12. PMID: 32559309; PMCID: PMC7323185.
- [20] Schaible UE, Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 2007 May;4(5):e115. https://doi.org/10.1371/ journal.pmed.0040115. PMID: 17472433; PMCID: PMC1858706.
- [21] Yang L, Liu J, Zhang R, Li M, Li Z, Zhou X, et al. Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: a descriptive study. J Clin Virol 2020 Aug;129:104475. https:// doi.org/10.1016/j.jcv.2020.104475. Epub 2020 May 26. PMID: 32485619; PMCID: PMC7250074.
- [22] Fock RA, Blatt SL, Beutler B, Pereira J, Tsujita M, de Barros FE, et al. Study of lymphocyte subpopulations in bone marrow in a model of protein-energy malnutrition. Nutrition 2010;26:1021–8.
- [23] Bedock D, Bel Lassen P, Mathian A, Moreau P, Couffignal J, Ciangura C, et al. Prevalence and severity of malnutrition in hospitalized COVID-19 patients. Clin Nutr ESPEN 2020 Dec;40:214–9. https://doi.org/10.1016/j.clnesp. 2020.09.018. Epub 2020 Sep 18. PMID: 33183539; PMCID: PMC7500887.
- [24] Whittle J, Molinger J, MacLeod D, Haines K, Wischmeyer PE, LEEP-COVID Study Group. Persistent hypermetabolism and longitudinal energy expenditure in critically ill patients with COVID-19. Crit Care 2020 Sep 28;24(1):581. https://doi.org/10.1186/s13054-020-03286-7. PMID: 32988390; PMCID: PMC7521195.
- [25] Schuetz P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. Lancet 2019;393:2312–21.
- [26] Thibault R, Coëffier M, Joly F, Bohé J, Schneider SM, Déchelotte P. How the Covid-19 epidemic is challenging our practice in clinical nutrition-feedback from the field. Eur J Clin Nutr 2020 Sep 16:1–10. https://doi.org/10.1038/ s41430-020-00757-6. Epub ahead of print. PMID: 32939042; PMCID: PMC7492685.
- [27] Heyland DK, Dhaliwal R, Jiang X, Day AG. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Crit Care 2011;15(6):R268.
- [28] Machado Dos Reis A, Marchetti J, Forte Dos Santos A, Franzosi OS, Steemburgo T. NUTRIC score: isolated and combined use with the NRS-2002 to predict hospital mortality in critically ill patients. JPEN - J Parenter Enter Nutr 2020 Sep;44(7):1250–6. https://doi.org/10.1002/jpen.1804. Epub 2020 Feb 6. PMID: 32026516.
- [29] Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al., the COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020 Jul 15:e203539. https://doi.org/10.1001/ jamainternmed.2020.3539.
- [30] Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltim) 2020 Nov 20;99(47):e23315. https://doi.org/10.1097/MD.000000000 023315. PMID: 33217868; PMCID: PMC7676531.
- [31] Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob 2020;19(1):18. pmid:32414383.
- [32] Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 2020;146: 128–136.e4.

M.L.G. Leoni, E. Moschini, M. Beretta et al.

- [33] Wang L. C-reactive protein levels in the early stage of COVID-19. Med Maladies Infect 2020.
- [34] Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of obesity with disease severity among patients with COVID-19. Obesity 2020; April;307.
- [35] Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its genetic predisposition with the risk of severe COVID-19: analysis of population-based cohort data. Metabolism 2020;112:154345. https://doi.org/10.1016/j.metabol.2020.154345.
- [36] Halasz G, Leoni ML, Villani GQ, Nolli M, Villani M. Obesity, overweight and survival in critically ill patients with SARS-CoV-2 pneumonia: is there an obesity paradox? Preliminary results from Italy. Eur J Prev Cardiol 2020 Jul 7. 2047487320939675.
- [37] Moonen HPFX, van Zanten FJL, Driessen L, de Smet V, Slingerland-Boot R, Mensink M, et al. Association of bioelectric impedance analysis body composition and disease severity in COVID-19 hospital ward and ICU patients: the BIAC-19 study. Clin Nutr 2020 Oct 21;S0261–5614(20):30551–3. https:// doi.org/10.1016/j.clnu.2020.10.023. Epub ahead of print. PMID: 33129597; PMCID: PMC7577288.
- [38] Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ 2020 Apr 7;369:m1328. https://doi.org/ 10.1136/bmj.m1328. Erratum in: BMJ. 2020 Jun 3;369:m2204. PMID: 32265220; PMCID: PMC7222643.
- [39] Martinuzzi ALN, Manzanares W, Quesada E, Reberendo MJ, Baccaro F, Aversa I, et al. Nutritional risk and clinical outcomes in critically ill adult patients with COVID-19. English Nutr Hosp 2021 Dec 9;38(6):1119–25. https://doi.org/ 10.20960/nh.03749. PMID: 34538061.

- [40] Osuna-Padilla IA, Rodríguez-Moguel NC, Aguilar-Vargas A, Rodríguez-Llamazares S. High nutritional risk using NUTRIC-Score is associated with worse outcomes in COVID-19 critically ill patients. Nutr Hosp 2021 Jun 10;38(3):540–4.
- [41] Acehan S, Gulen M, Isıkber C, Unlu N, Sumbul HE, Gulumsek E, et al. mNUTRIC tool is capable to predict nutritional needs and mortality early in patients suffering from severe pneumonia. Clin Nutr ESPEN 2021 Oct;45:184–91.
- [42] Kumar N, Kumar A, Kumar A, Pattanayak A, Singh K, Singh PK. NUTRIC score as a predictor of outcome in COVID-19 ARDS patients: a retrospective observational study. Indian J Anaesth 2021 Sep;65(9):669–75.
- [43] Lin J, Ke L, Doig GS, Ye B, Jiang Z, Liu Z, et al. Chinese Critical Care Nutrition Trials Group (CCCNTG). Nutritional practice in critically ill COVID-19 patients: a multicenter ambidirectional cohort study in Wuhan and Jingzhou. Asia Pac J Clin Nutr 2021;30(1):15–21.
- [44] Li G, Zhou CL, Ba YM, Wang YM, Song B, Cheng XB, et al. Nutritional risk and therapy for severe and critical COVID-19 patients: a multicenter retrospective observational study. Clin Nutr 2021 Apr;40(4):2154–61.
- [45] Liberti A, Piacentino E, Umbrello M, Muttini S. Comparison between Nutric Score and modified nutric score to assess ICU mortality in critically ill patients with COVID-19. Clin Nutr ESPEN 2021 Aug;44:479–82.
- [46] Leoni MLG, Lombardelli L, Colombi D, Bignami EG, Pergolotti B, Repetti F, et al. Prediction of 28-day mortality in critically ill patients with COVID-19: development and internal validation of a clinical prediction model. PLoS One 2021 Jul 13;16(7):e0254550.
- [47] Don BR, George K. Poor nutritional status and inflammation: serum albumin: relationship to inflammation and nutrition. Semin Dial 2004;17:6.
- [48] Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002 Apr 15;65(8):1575–8.